Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium adolescentis CCFM1061
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium adolescentis CCFM1061 is a specific probiotic bacterial strain being investigated as a live biotherapeutic product (LBP) for the treatment of metabolic disorders, particularly type 2 diabetes. Isolated and maintained by Jiangnan University in the Culture Collection of Food Microorganisms (CCFM), the strain has demonstrated significant anti-diabetic effects in preclinical models, including the reduction of fasting blood glucose levels, improvement of oral glucose tolerance, and amelioration of insulin resistance. Its efficacy in these models has been reported as comparable to the thiazolidinedione drug rosiglitazone. Additionally, CCFM1061 has been shown to improve lipid profiles (total cholesterol and HDL-C) and exhibits rapid intestinal colonization, suggesting potential for restoring gut microbiota balance to manage metabolic health.
- Other names
- 青春双歧杆菌CCFM1061
Beyond the preview
Go deeper on bifidobacterium adolescentis CCFM1061.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium adolescentis CCFM1061.